Enfusion, Inc. (NYSE:ENFN) Short Interest Update

Enfusion, Inc. (NYSE:ENFN) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 1,900,000 shares, a decrease of 17.7% from the August 15th total of 2,310,000 shares. Based on an average trading volume of 374,600 shares, the short-interest ratio is presently 5.1 days. Approximately 3.9% of the shares of the stock are short sold.

Insider Transactions at Enfusion

In related news, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $8.11, for a total transaction of $147,934.51. Following the sale, the insider now owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC bought a new position in Enfusion during the first quarter valued at $44,000. RiverPark Advisors LLC acquired a new position in Enfusion during the 2nd quarter valued at about $68,000. Arizona State Retirement System purchased a new stake in Enfusion in the second quarter valued at about $86,000. Price T Rowe Associates Inc. MD purchased a new stake in Enfusion in the first quarter valued at about $102,000. Finally, Quadrature Capital Ltd acquired a new stake in Enfusion in the first quarter worth about $109,000. Institutional investors own 81.05% of the company’s stock.

Enfusion Stock Up 0.8 %

ENFN opened at $8.80 on Wednesday. The company has a market capitalization of $1.13 billion, a PE ratio of 291.00, a price-to-earnings-growth ratio of 2.23 and a beta of 0.90. The firm has a 50-day simple moving average of $8.52 and a two-hundred day simple moving average of $8.87. Enfusion has a 52 week low of $7.52 and a 52 week high of $10.45.

Enfusion (NYSE:ENFN) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). Enfusion had a net margin of 1.98% and a return on equity of 6.17%. The firm had revenue of $49.46 million for the quarter, compared to the consensus estimate of $50.27 million. As a group, sell-side analysts expect that Enfusion will post 0.07 earnings per share for the current year.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.